IBDEI305 ; ; 19-NOV-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,50328,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,50328,1,3,0)
 ;;=3^Sacoid Meningitis
 ;;^UTILITY(U,$J,358.3,50328,1,4,0)
 ;;=4^D86.81
 ;;^UTILITY(U,$J,358.3,50328,2)
 ;;=^5002446
 ;;^UTILITY(U,$J,358.3,50329,0)
 ;;=D86.85^^219^2447^45
 ;;^UTILITY(U,$J,358.3,50329,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,50329,1,3,0)
 ;;=3^Sacoid Myocarditis
 ;;^UTILITY(U,$J,358.3,50329,1,4,0)
 ;;=4^D86.85
 ;;^UTILITY(U,$J,358.3,50329,2)
 ;;=^5002450
 ;;^UTILITY(U,$J,358.3,50330,0)
 ;;=D86.87^^219^2447^46
 ;;^UTILITY(U,$J,358.3,50330,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,50330,1,3,0)
 ;;=3^Sacoid Myositis
 ;;^UTILITY(U,$J,358.3,50330,1,4,0)
 ;;=4^D86.87
 ;;^UTILITY(U,$J,358.3,50330,2)
 ;;=^5002452
 ;;^UTILITY(U,$J,358.3,50331,0)
 ;;=D86.84^^219^2447^47
 ;;^UTILITY(U,$J,358.3,50331,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,50331,1,3,0)
 ;;=3^Sacoid Pyelonephritis
 ;;^UTILITY(U,$J,358.3,50331,1,4,0)
 ;;=4^D86.84
 ;;^UTILITY(U,$J,358.3,50331,2)
 ;;=^5002449
 ;;^UTILITY(U,$J,358.3,50332,0)
 ;;=D86.0^^219^2447^48
 ;;^UTILITY(U,$J,358.3,50332,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,50332,1,3,0)
 ;;=3^Sarcoidosis of Lung
 ;;^UTILITY(U,$J,358.3,50332,1,4,0)
 ;;=4^D86.0
 ;;^UTILITY(U,$J,358.3,50332,2)
 ;;=^5002442
 ;;^UTILITY(U,$J,358.3,50333,0)
 ;;=D86.2^^219^2447^49
 ;;^UTILITY(U,$J,358.3,50333,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,50333,1,3,0)
 ;;=3^Sarcoidosis of Lung w/ Sarcoidosis of Lymph Nodes
 ;;^UTILITY(U,$J,358.3,50333,1,4,0)
 ;;=4^D86.2
 ;;^UTILITY(U,$J,358.3,50333,2)
 ;;=^5002444
 ;;^UTILITY(U,$J,358.3,50334,0)
 ;;=D86.1^^219^2447^50
 ;;^UTILITY(U,$J,358.3,50334,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,50334,1,3,0)
 ;;=3^Sarcoidosis of Lymph Nodes
 ;;^UTILITY(U,$J,358.3,50334,1,4,0)
 ;;=4^D86.1
 ;;^UTILITY(U,$J,358.3,50334,2)
 ;;=^5002443
 ;;^UTILITY(U,$J,358.3,50335,0)
 ;;=D86.89^^219^2447^51
 ;;^UTILITY(U,$J,358.3,50335,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,50335,1,3,0)
 ;;=3^Sarcoidosis of Oth Sites
 ;;^UTILITY(U,$J,358.3,50335,1,4,0)
 ;;=4^D86.89
 ;;^UTILITY(U,$J,358.3,50335,2)
 ;;=^5002453
 ;;^UTILITY(U,$J,358.3,50336,0)
 ;;=D86.3^^219^2447^52
 ;;^UTILITY(U,$J,358.3,50336,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,50336,1,3,0)
 ;;=3^Sarcoidosis of Skin
 ;;^UTILITY(U,$J,358.3,50336,1,4,0)
 ;;=4^D86.3
 ;;^UTILITY(U,$J,358.3,50336,2)
 ;;=^5002445
 ;;^UTILITY(U,$J,358.3,50337,0)
 ;;=D86.9^^219^2447^53
 ;;^UTILITY(U,$J,358.3,50337,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,50337,1,3,0)
 ;;=3^Sarcoidosis,Unspec
 ;;^UTILITY(U,$J,358.3,50337,1,4,0)
 ;;=4^D86.9
 ;;^UTILITY(U,$J,358.3,50337,2)
 ;;=^5002454
 ;;^UTILITY(U,$J,358.3,50338,0)
 ;;=M35.01^^219^2447^54
 ;;^UTILITY(U,$J,358.3,50338,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,50338,1,3,0)
 ;;=3^Sicca Syndrome w/ Keratoconjunctivitis
 ;;^UTILITY(U,$J,358.3,50338,1,4,0)
 ;;=4^M35.01
 ;;^UTILITY(U,$J,358.3,50338,2)
 ;;=^5011787
 ;;^UTILITY(U,$J,358.3,50339,0)
 ;;=M35.02^^219^2447^55
 ;;^UTILITY(U,$J,358.3,50339,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,50339,1,3,0)
 ;;=3^Sicca Syndrome w/ Lung Involvement
 ;;^UTILITY(U,$J,358.3,50339,1,4,0)
 ;;=4^M35.02
 ;;^UTILITY(U,$J,358.3,50339,2)
 ;;=^5011788
 ;;^UTILITY(U,$J,358.3,50340,0)
 ;;=M35.03^^219^2447^56
 ;;^UTILITY(U,$J,358.3,50340,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,50340,1,3,0)
 ;;=3^Sicca Syndrome w/ Myopathy
 ;;^UTILITY(U,$J,358.3,50340,1,4,0)
 ;;=4^M35.03
 ;;^UTILITY(U,$J,358.3,50340,2)
 ;;=^5011789
 ;;^UTILITY(U,$J,358.3,50341,0)
 ;;=M35.09^^219^2447^57
 ;;^UTILITY(U,$J,358.3,50341,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,50341,1,3,0)
 ;;=3^Sicca Syndrome w/ Oth Organ Involvement
